PTCT, US69366J2006

UBS lifts PTC Therapeutics stock target to USD 90.00

Published on 10/15/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 360.52 million, up 101.50 percent year over year. PTC Therapeutics stock costs EUR 54.37 on October 15, 2026.

Analyst view and market levels

UBS lifted its PTC Therapeutics target to USD 90.00 on October 14, 2026.
Second-quarter revenue reached USD 360.52 million, up 101.50 percent from a year earlier.
PTC Therapeutics stock costs EUR 54.37 at Lang & Schwarz on October 15, 2026 at 10:32 p.m. CEST.
PTC Therapeutics carried a market capitalization of USD 5.1 billion as of October 15, 2026.

PTCT, US69366J2006, Illustration mit AI erstellt.

UBS lifted its price target for PTC Therapeutics to USD 90.00 from USD 80.00 on October 14, 2026, while maintaining a Buy rating, according to Markets Insider. The target is in the same currency as the Nasdaq listing and gives investors a fresh analyst reference for the rare-disease company. PTC Therapeutics stock was trading at EUR 54.37 at Lang & Schwarz on October 15, 2026 at 10:32 p.m. CEST.

Revenue and earnings in second quarter

PTC Therapeutics reported USD 360.52 million in revenue for the second quarter of 2026, up 101.50 percent from USD 178.88 million in the second quarter of 2025. Net profit reached USD 83.50 million, compared with a GAAP net loss of USD 64.85 million a year earlier, according to Markets Insider. The earnings comparison is the main operating counterweight to the stock's valuation risk.

Price position and valuation

The Nasdaq quote was USD 60.99 on October 15, 2026 at 4:00 p.m. ET, with a USD 58.80 to USD 90.87 52-week range. The stock's market capitalization was USD 5.1 billion, and its trailing price-to-earnings ratio was minus 105.16. PTC Therapeutics traded 33.10 percent above its 52-week low and 32.88 percent below its 52-week high, calculated from the same Nasdaq figures.

PTC Therapeutics had scheduled its third-quarter 2026 results for October 29, 2026, with a webcast at 4:30 p.m. ET, according to StockTitan. The date gives the market a defined checkpoint for testing whether the second-quarter growth rate is carrying into the next reporting period.

Comparison with peers

PTC Therapeutics (Nasdaq, USD): P/E minus 105.16, market capitalization USD 5.1 billion

Sarepta Therapeutics (Nasdaq, USD): plus 5.70 percent, P/E minus 6.13, market capitalization USD 1.9 billion

BioMarin Pharmaceutical (Nasdaq, USD): plus 1.65 percent, P/E 143.72, market capitalization USD 10.8 billion

Market levels frame the stock

PTC Therapeutics combines a sharp year-over-year revenue comparison with a high-growth valuation profile. The UBS target and the October 29 reporting date give investors two dated markers, while the Nasdaq range shows how far the current USD quote remains from its yearly extremes.

The further course of trading is shown by the continuously updated real-time quote of PTC Therapeutics stock.